People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ONL Therapeutics, Inc. | — | Biotechnology | Series C | $111.5M | $495.5M | 2020 |
| Trefoil Therapeutics, Inc. | — | Biotechnology | Series A | $33.3M | $16.2M | 2019 |
| Azitra Inc | — | Biotechnology | Series B | $32.1M | $66.8M | 2017 |
| i-Lumen Scientific, Inc. | — | Other Health Care | Series B | $18.8M | $231.7M | 2022 |
Stella Robertson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stella Robertson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Wagner | 1 | 13 |
| Michal Silverberg | 1 | 7 |
| Lucio Iannone | 1 | 6 |
| Christy Shaffer | 1 | 6 |
| Aaron Fletcher | 1 | 5 |
| Marian Nakada | 1 | 4 |
| Derek Yoon | 1 | 4 |
| John Fucci | 1 | 3 |
| Cain McClary | 1 | 3 |
| Jonathan Mow | 1 | 3 |
| Travis Whitfill | 1 | 3 |
| Rafael Castilla | 1 | 3 |
| Gregory Cash | 1 | 2 |
| Jay Schwartz | 1 | 2 |
| Richard Andrews | 1 | 2 |
| Brian Mower | 1 | 2 |
| Chris Pulling | 1 | 2 |
| Michael Glover | 1 | 2 |
| Felicia David-Visser | 1 | 2 |
| Greg Cash | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.